Press Release Details

Cerus Corporation to Present at the Fourth Annual Needham Biotechnology Conference

May, 05 2005

CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) today announced that Claes Glassell, president and CEO, William J. Dawson, vice president, finance and CFO, and David N. Cook, vice president of research and development, will present on Wednesday, May 25, 2005, at 2:30 p.m. Eastern Time during the Fourth Annual Needham Biotechnology Conference.

The conference is being held at the New York Palace Hotel in New York City. Interested parties can access a live or archived Internet broadcast of the presentation at The presentation will be archived for 30 days.

About Cerus

Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products through alliances. Cerus' partners to date include MedImmune and Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Helinx is a trademark of Cerus Corporation

Baxter and INTERCEPT are trademarks of Baxter International Inc.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600